The clinical symptoms and signs of methamphetamine-associated psychosis (MAP) and schizophrenia are highly similar, but the situation is completely different when MAP and schizophrenia patients need to be assessed for criminal responsibility after they comitted a harmful behavior. Therefore, the distinction between the two psychoses is very important in forensic psychiatry. At present, the identification of these two psychoses is mainly dependent on the corresponding criteria such as the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and the Chinese Classification of Mental Disorders Version 3 (CCMD-3). It's challenging to diagnose and distinguish between the two in practical cases due to their similar clinical symptoms and the lack of effective objective indexes. Different from the limitations of single omics, integrative omics intergrates data from multiple dimensions and has been extensively studied in the field of schizophrenia and has achieved some preliminary results. In view of the correlation between MAP and schizophrenia and the potential application value of integrative omics, this paper proposes an integrative omics strategy for MAP pathogenesis and forensic identification, aiming to improve the further understanding of the relationship between the two psychoses and the corresponding pathogenesis. It also provides references for the future exploration of integrative omics in forensic precise identification and effective monitoring and early warning methods.
Humans ; Methamphetamine/adverse effects* ; Psychoses, Substance-Induced/etiology* ; Psychotic Disorders/genetics* ; Schizophrenia/genetics* ; Diagnosis, Differential

No abstract available.
Psychotic Disorders

No abstract available.
Psychotic Disorders*

OBJECTIVES: Delusions are prevalent even among members of the general population, and persecutory delusions (PDs) and grandiose delusions (GDs) are most frequently found. In this study, we investigated the differences in the dimensions of delusional ideation, reported psychosis proneness, and subjective psychotic symptoms in nonclinical individuals stratified according to the existence of PDs and GDs. METHODS: A total of 311 nonclinical individuals completed the Peters et al Delusions Inventory 40 (PDI-40), Perceptual Aberration Scale (PAS), Magical Ideation Scale (MIS), Schizotypal Personality Scale (STA), and Symptom Check List-90-R (SCL-90-R). Individuals were grouped according to four types based on the existence of PDs and GDs in PDI-40 items. RESULTS: An analysis of variance revealed that the four groups differed significantly in total delusion score, distress, preoccupation, and conviction level of delusional ideation, PAS, MAS, STA, in total SCL-90-R scores, and all SCL-90-R sub symptoms. In post-hoc analysis, the group with both PDs and GDs showed the highest scores in all measures, compared with the other three groups. CONCLUSION: We found that individuals with both PDs and GDs have a tendency to possess another delusional ideation and reported more distress, preoccupation, and conviction level of delusional ideation, psychosis proneness, and subjective symptoms. Existence of both PDs and GDs significantly elevated psychosis proneness in comparison to having only either one of them.
Delusions ; Magic ; Psychotic Disorders

No abstract available.
Humans ; Psychotic Disorders* ; Schizophrenia*

No abstract available.
Dexamethasone* ; Psychotic Disorders*

No abstract available.
Psychotic Disorders* ; Turner Syndrome*

No abstract available.
Cheek* ; Humans ; Psychotic Disorders*

No abstract available.
Meningoencephalitis* ; Psychotic Disorders*

A cross – sectional study on 40 psychotic patients who were treated in National Institute of Mental Health from March to December 2003 showed that the causes of delay for the patients go to mental health services are onset of mental disorders, lack of knowledge on mental health of patients and their relatives (75%), short of caring for patients (30%), unavailability of mental health services (10%) and difficulties of expenses (10%)
Psychotic Disorders ; Therapeutics